Video

Dr. Eric Klein on genomic testing for genitourinary cancers

Author(s):

Urology Times staff

“It’s really fascinating how the field is expanding,” Klein says.

“[Genomic testing is] going to be a routine part of prostate cancer care and urologic cancer care going forward,” Eric A. Klein, MD, says in this video. Klein is the Chairman of the Glickman Urological & Kidney Institute and a staff member in the Taussig Cancer Institute at Cleveland Clinic.

Related Videos
Amy E. Krambeck, MD, answers a question during a Zoom video interview
Channing J. Paller, MD, answers a question during a Zoom video interview
Vanita Gaglani, RPT, answers a question during a video interview
Channing J. Paller, MD, answers a question during a Zoom video interview
Raveen Syan, MD, FPMRS, answers a question during a video interview
Related Content
MPS2 test validated for detection of high-grade prostate cancer in non-DRE urine
January 30th 2025

MPS2 test validated for detection of high-grade prostate cancer in non-DRE urine

Hannah Clarke
“MPS2 could potentially improve the health of our patients by avoiding overdiagnosis and overtreatment and allowing us to focus on those who are most likely to have aggressive cancers," says Ganesh S. Palapattu, MD, FACS.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Black men cite lack of invitation, information as key barriers to prostate cancer trials
January 27th 2025

Black men cite lack of invitation, information as key barriers to prostate cancer trials

Hannah Clarke
According to the authors, these findings highlight the need to more effectively include Black men in prostate cancer research.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Standard pathology reports may be difficult to understand for patients with prostate cancer
January 23rd 2025

Standard pathology reports may be difficult to understand for patients with prostate cancer

Hannah Clarke
Overall, 39% of those who received a university-formatted report and 56% of those who received a VA-formatted report were able to identify that they had prostate cancer.
Health-related QOL is comparable among ARPI regimens for CSPC
January 23rd 2025

Health-related QOL is comparable among ARPI regimens for CSPC

Hannah Clarke
At 25 weeks, FACT-P total score remained comparable between the arms.
© 2025 MJH Life Sciences

All rights reserved.